









Markets
/
Stocks
/
nasdaq-bnr
/

Burning Rock Biotech Ltd

BNR

11.310USD

-0.950-7.75%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

102.12MMarket Cap

LossP/E TTM



Burning Rock Biotech Ltd

11.310

-0.950-7.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Burning Rock Biotech Ltd

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Burning Rock Biotech Ltd's Score

Industry at a Glance

Industry Ranking

58 / 78

Overall Ranking

329 / 4616

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Burning Rock Biotech Ltd Highlights

StrengthsRisks

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

Growing

The company is in a growing phase, with the latest annual income totaling USD 71.08M.

Undervalued

The company’s latest PE is -6.03, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.61M shares, increasing 6.93% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 31.72K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 9.29, which is higher than the Healthcare Providers & Services industry's average of 7.24. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.84M, representing a year-over-year increase of 9.53%, while its net profit experienced a year-over-year increase of 91.03%.

Score

Industry at a Glance

Previous score

9.29

Change



Financials

9.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.75

Key Metrics

Free cash flow

No Data

Burning Rock Biotech Ltd's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.18, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -6.03, which is -106.48% below the recent high of 0.39 and -19.01% above the recent low of -7.17.

Score

Industry at a Glance

Previous score

7.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Healthcare Providers & Services industry's average is 7.56.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.13, which is higher than the Healthcare Providers & Services industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 14.13 and the support level at 8.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.59

Change

-1.46

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.335

Buy

RSI(14)

55.335

Neutral

STOCH(KDJ)(9,3,3)

52.185

Sell

ATR(14)

1.095

High Vlolatility

CCI(14)

22.104

Neutral

Williams %R

43.803

Buy

TRIX(12,20)

1.668

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

12.389

Sell

MA10

11.982

Sell

MA20

10.288

Buy

MA50

9.364

Buy

MA100

7.474

Buy

MA200

6.005

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 51.07%, representing a quarter-over-quarter decrease of 14.96%. The largest institutional shareholder is James Simons, holding a total of 31.72K shares, representing 0.35% of shares outstanding, with 1.84% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Northern Light Venture Capital

1.05M

Kynam Capital Management LP

994.88K

Lyfe Capital

833.84K

China Merchants Bank Co Ltd

462.99K

Quantum Boundary Holdings Ltd

353.92K

+10637.83%

CRCM L.P.

194.77K

-13.93%

Amova Asset Management Americas, Inc

45.55K

Amova Asset Management Co., Ltd.

43.93K

Renaissance Technologies LLC

Star Investors

31.72K

BofA Global Research (US)

29.28K

-0.06%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.60, which is lower than the Healthcare Providers & Services industry's average of 5.44. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.